Literature DB >> 33826004

Enhanced Recovery After Major Gastrectomy for Cancer.

Yinin Hu1, Annie W Hsu2, Vivian E Strong3.   

Abstract

Enhanced recovery after surgery (ERAS) protocols have gained increasing popularity over the past 10 years, and its overarching objectives are to improve perioperative morbidity and reduce postoperative length of stay. Consensus guidelines from the ERAS Society specific to major gastrectomy were published in 2014, however since that time, prospective and retrospective studies have expanded the collective evidence for both the content and efficacy of ERAS pathways for gastrectomy. This objective of this review was to summarize recent data pertinent to the preoperative, perioperative, and postoperative management of gastrectomy patients along an ERAS pathway.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh：

Year:  2021        PMID： 33826004      PMCID： PMC8721661          DOI： 10.1245/s10434-021-09906-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


  29 in total

1.  Hospital stay of 2 days after open sigmoidectomy with a multimodal rehabilitation programme.

Authors:  H Kehlet; T Mogensen
Journal:  Br J Surg       Date:  1999-02       Impact factor: 6.939

2.  Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study.

Authors:  Derek B Hennessey; John P Burke; Tara Ni-Dhonochu; Conor Shields; Desmond C Winter; Kenneth Mealy
Journal:  Ann Surg       Date:  2010-08       Impact factor: 12.969

3.  Attenuation of the systemic inflammatory response and infectious complications after gastrectomy with preoperative oral arginine and omega-3 fatty acids supplemented immunonutrition.

Authors:  Yoshiki Okamoto; Keiichi Okano; Kunihiko Izuishi; Hisashi Usuki; Hisao Wakabayashi; Yasuyuki Suzuki
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

4.  Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer.

Authors:  K Fujitani; T Tsujinaka; J Fujita; I Miyashiro; H Imamura; Y Kimura; K Kobayashi; Y Kurokawa; T Shimokawa; H Furukawa
Journal:  Br J Surg       Date:  2012-02-24       Impact factor: 6.939

5.  Albumin supplementation in the critically ill. A prospective, randomized trial.

Authors:  E F Foley; B C Borlase; W H Dzik; B R Bistrian; P N Benotti
Journal:  Arch Surg       Date:  1990-06

6.  Personalised Prehabilitation in High-risk Patients Undergoing Elective Major Abdominal Surgery: A Randomized Blinded Controlled Trial.

Authors:  Anael Barberan-Garcia; Marta Ubré; Josep Roca; Antonio M Lacy; Felip Burgos; Raquel Risco; Dulce Momblán; Jaume Balust; Isabel Blanco; Graciela Martínez-Pallí
Journal:  Ann Surg       Date:  2018-01       Impact factor: 12.969

7.  Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations.

Authors:  K Mortensen; M Nilsson; K Slim; M Schäfer; C Mariette; M Braga; F Carli; N Demartines; S M Griffin; K Lassen
Journal:  Br J Surg       Date:  2014-07-21       Impact factor: 6.939

8.  Randomized Controlled Trial of Extended Perioperative Counseling in Enhanced Recovery After Colorectal Surgery.

Authors:  Håvard Mjørud Forsmo; Christian Erichsen; Anne Rasdal; Jon Meyer Tvinnereim; Hartwig Körner; Frank Pfeffer
Journal:  Dis Colon Rectum       Date:  2018-06       Impact factor: 4.585

9.  The effect of interactive multimedia on preoperative knowledge and postoperative recovery of patients undergoing laparoscopic cholecystectomy.

Authors:  A Stergiopoulou; K Birbas; T Katostaras; J Mantas
Journal:  Methods Inf Med       Date:  2007       Impact factor: 2.176

10.  The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis.

Authors:  Alfred Adiamah; Pavel Skořepa; Arved Weimann; Dileep N Lobo
Journal:  Ann Surg       Date:  2019-08       Impact factor: 12.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.